Streetbeat News

Analyst Ratings

CANF

Can-Fite BioPharma Ltd. (NYSE:CANF) announced that its study on the treatment of pancreatic carcinoma with Namodenoson has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer. The study showed significant growth inhibition in pancreatic carcinoma patient cells treated with Namodenoson. Can-Fite is planning to submit an exploratory Phase II protocol for approval in Israel and the U.S.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:05 am

GLDG

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on GoldMining (AMEX:GLDG), but has lowered the price target from $5.25 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:04 am

VALN

Needham analyst Edward White has reiterated a 'Buy' rating on Valneva (NASDAQ:VALN) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:01 am

FLNC

HSBC analyst Sean McLoughlin maintains a Buy rating on Fluence Energy (NASDAQ:FLNC) and raises the price target from $31 to $32.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:00 am

ZIM

JP Morgan analyst Samuel Bland has maintained an Overweight rating on ZIM Integrated Shipping (NYSE:ZIM) but lowered the price target from $15.4 to $14.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:57 am

IMVT

Citigroup analyst Samantha Semenkow maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $33 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:53 am

PDSB

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:52 am

VERU

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Veru (NASDAQ:VERU) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:50 am

MOTS

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Motus GI Hldgs (NASDAQ:MOTS) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:49 am

ROIV

Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 10:48 am